跳至主要内容
临床试验/NL-OMON51767
NL-OMON51767招募中不适用

COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events - COMBINE-INTERVENE trial

Diagram B.V.0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Patients undergoing PCI, aged 30-80 years with any clinical presentation
  • 2. Angiographic criteria: presence of >= 2 de novo target lesions* located in 2
  • different native coronary arteries feasible for treatment with PCI (operator /
  • Heart team decision)
  • Angiographic criteria target lesion* (all criteria I-IV should be applicable):
  • I. diameter stenosis >= 50% on visual estimation
  • II. de novo lesion located in native (non-grafted) vessel
  • III. lesion reference diameter of >= 2.0 mm
  • IV. Thrombolysis In Myocardial Infarction (TIMI) 3 flow in all vessels (with
  • exclusion of culprit lesions)
  • *Target lesions are either culprit myocardial infarction lesions or lesions
  • where FFR will be performed. Patients are eligible if they have >= 2 target
  • lesions or one culprit and >= 1 target lesion.

排除标准

  • 1. Patients with multivessel disease requiring coronary artery bypass grafting
  • (CABG) treatment (operator / local heart team decision)
  • 2. Lesion located in a grafted segment or in a vein graft
  • 3. In-stent restenosis lesions
  • 4. Left main trifurcation
  • 5. Left main lesion stand-alone (without other lesions)
  • 6. Patients with severe tortuous lesions (where FFR and OCT is judged
  • impossible or dangerous)
  • 7. Chronic total occlusion
  • 8. Spontaneous coronary dissection
  • 9. Patients with severe valvular heart disease likely to require cardiac
  • surgery within the next 2 years
  • 10. Patients with left ventricle (LV) function less than 30%
  • 11. Renal insufficiency (Glomerular Filtration Rate (GFR) < 29 ml/min/1.73m2;
  • Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5)
  • 12. Life expectancy less than 3 years

研究者

发起方
Diagram B.V.

相似试验

COMBINEd Ischemia and Vulnerable Plaque Percutaneous... | 临床试验